Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows.
Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates On MultiStem Clinical Programs In Japan
Athersys, Inc. (NASDAQ:ATHX) announced today that its partner, HEALIOS K.K. (Healios), has provided updates on its two clinical programs evaluating MultiStem® (invimestrocel, HLCM051) cell therapy, for which Healios
Recap: Athersys Q4 Earnings
Athersys (NASDAQ:ATHX) reported its Q4 earnings results on Tuesday, March 15, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Athersys missed estimated earnings by 28.57%, reporting an EPS of $-0.09 versus an estimate of $-0.07.
Earnings Preview: Athersys
Athersys (NASDAQ:ATHX) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement.
Analysts estimate that Athersys will report an earnings per share (EPS) of $-0.07.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours.
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.